Publication & Citation Trends
Most Cited Works
Publications
60 total
Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt’s lymphoma anti-tumor activity PDF
Cited by 151
OpenAlex
Whole transcriptome profiling of patient-derived xenograft models as a tool to identify both tumor and stromal specific biomarkers PDF
Cited by 43
OpenAlex
Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors
Cited by 72
OpenAlex
The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models PDF
Cited by 111
OpenAlex
Enhanced Apoptosis and Tumor Growth Suppression Elicited by Combination of MEK (Selumetinib) and mTOR Kinase Inhibitors (AZD8055)
Cited by 84
OpenAlex
Benefits of mTOR kinase targeting in oncology: pre-clinical evidence with AZD8055
Cited by 37
OpenAlex
The Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) Enhances the Radiation Responsiveness of Lung and Colorectal Tumor Xenografts PDF
Cited by 51
OpenAlex
Research Topics
PI3K/AKT/mTOR signaling in cancer
(19)
Cancer, Hypoxia, and Metabolism
(17)
Melanoma and MAPK Pathways
(15)
Cancer Mechanisms and Therapy
(7)
Glioma Diagnosis and Treatment
(6)
Frequent Co-Authors
Affiliations
AstraZeneca (United Kingdom)
Centre National de la Recherche Scientifique
Academy of Medical Sciences
Inserm
Guangdong General Hospital